Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

21.82
+0.14000.65%
Post-market: 21.820.00000.00%19:30 EDT
Volume:617.37K
Turnover:13.50M
Market Cap:1.40B
PE:-6.29
High:22.37
Open:21.62
Low:21.16
Close:21.68
52wk High:22.54
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.80
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.36
PE(LYR):-5.86

Loading ...

Cullinan presents initial Phase 1 CLN-978 data in refractory RA, SLE at EULAR 2026

Reuters
·
May 19

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

GlobeNewswire
·
May 19

AnaptysBio names Christopher Murphy as CFO

Reuters
·
May 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 08

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

TIPRANKS
·
May 08

Analysts’ Top Healthcare Picks: Cullinan Management (CGEM), Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
May 08

Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Benzinga Earnings
·
May 07

Cullinan Therapeutics Q1 net loss widens

Reuters
·
May 07

BRIEF-Cullinan Therapeutics Q1 Operating Expenses USD 53.697 Million

Reuters
·
May 07

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Cullinan CSO Jennifer Michaelson disposes 8,000 shares for $117,916

Reuters
·
May 07

Cullinan jumps after UCB acquires Candid Therapeutics

TIPRANKS
·
May 04

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 04

Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 29

Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright

TIPRANKS
·
Apr 29

Cullinan Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $27 From $26

THOMSON REUTERS
·
Apr 29

BRIEF-Cullinan Therapeutics Inc Files For Mixed Shelf Offering

Reuters
·
Apr 28

Cullinan Therapeutics Inc: Files for Mixed Shelf Offering - SEC Filing

THOMSON REUTERS
·
Apr 28